ABEO — Abeona Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $206.53m
- $154.30m
- $3.50m
Annual cashflow statement for Abeona Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -76.3 | -84.2 | -84.9 | -39.7 | -54.2 |
| Depreciation | |||||
| Non-Cash Items | 9.2 | 43 | 34.3 | -0.988 | 16.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.55 | 1.63 | -18.3 | -5.89 | -1.79 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -62.8 | -35 | -65.7 | -43.5 | -37 |
| Capital Expenditures | -6.51 | -1.34 | -4.15 | -0.13 | -0.331 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 66.5 | -82.4 | 70.2 | -23.8 | 0.539 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 60 | -83.7 | 66.1 | -24 | 0.208 |
| Financing Cash Flow Items | — | — | — | — | -0.15 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 114 | 1.94 | 24.9 | 43.2 | 37.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 111 | -117 | 25.3 | -24.3 | 0.256 |